Aclaris Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Aclaris Therapeutics, Inc. (ACRS) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $1.78 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.67.
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $1.26, a 91.63% decline year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $15.06.
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2018-03-31 was $8.43, a 42.40% increase year-over-year.
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $1.31, a 0.00% change from fiscal 2023.
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.31, a 26.40% decline from fiscal 2022.
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.78, a 85.91% decline from fiscal 2021.
- Aclaris Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $12.63, a 871.54% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.78 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $1.67 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | $1.31 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $0.72 10-Q · filed 2024-11-06 | |||
| 2023-12-31 | $1.31 10-K · filed 2025-02-27 | |||
| 2023-09-30 | $1.30 10-Q · filed 2023-11-06 | |||
| 2023-06-30 | $1.20 10-Q · filed 2023-08-07 | |||
| 2022-12-31 | $1.78 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $1.40 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $1.40 10-Q · filed 2022-08-03 | |||
| 2022-03-31 | $1.26 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $12.63 10-K · filed 2024-02-27 | |||
| 2021-09-30 | $12.63 10-Q · filed 2021-11-02 | |||
| 2021-06-30 | $12.63 10-Q · filed 2021-08-05 | |||
| 2021-03-31 | $15.06 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $1.30 10-K · filed 2023-02-23 | |||
| 2019-12-31 | $1.33 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $1.29 10-Q · filed 2019-11-07 | |||
| 2019-06-30 | $1.52 10-Q · filed 2019-08-08 | |||
| 2018-12-31 | $9.70 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $9.70 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | $8.43 10-Q · filed 2018-08-03 | |||
| 2018-03-31 | $8.43 10-Q · filed 2018-05-08 | |||
| 2017-12-31 | $6.40 10-K · filed 2020-02-25 | |||
| 2017-09-30 | $6.40 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | $6.40 10-Q · filed 2017-08-08 | |||
| 2017-03-31 | $5.92 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $2.37 10-K · filed 2017-03-15 | |||
| 2016-09-30 | $0.55 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $0.41 10-Q · filed 2016-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |